| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Molecular and Cellular Biology [J. A. T., S. J. M., T. D. D., D. R. R.] and Pathology [G. E. A.], Baylor College of Medicine, Houston, Texas 77030
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Recent studies have addressed the role of stroma in promoting tumorigenesis using experimental carcinoma models. Elenbaas et al. (9) have shown that combining transformed human mammary epithelium (derived from normal glands) with normal human mammary fibroblasts elevated the incidence of tumor formation to 100% as compared with a 52% incidence in the control (epithelium only). Moreover, these studies showed that coinjection of normal fibroblasts with transformed mammary epithelium reduced the tumor latency period from 52 to 20 days. Similarly, another study showed that the coinoculation of carcinoma-associated fibroblasts with initiated, but not tumorigenic, prostate epithelium resulted in increased tumor incidence and growth (10) . Together, these data show that when all other parameters are constant, the stromal microenvironment in cancer plays a critical role in determining the incidence and rate of tumorigenesis.
The specific mechanisms and pathways through which reactive stroma regulates carcinoma tumorigenesis are not fully understood. It is known that in human prostate cancer, markers of reactive stroma are observed quite early in tumor development. The activation of stromal cells to the myofibroblast phenotype and stimulated expression of specific ECM components were observed in the stroma immediately adjacent to precancerous PIN lesions in human surgical specimens.4 These stromal regions adjacent to PIN have also been reported to exhibit elevated microvessel density relative to normal prostate stroma (11, 12, 13) . Accordingly, reactive stroma is likely to function early in tumorigenesis, possibly during precancerous stages.
It is clear that the ability to model reactive stroma in an animal system would aid in advancing our understanding of specific mechanisms (14) . Currently, there is no promoter with which to target gene expression exclusively to the stromal compartment of a specific tissue in transgenic animals. Accordingly, xenografts of human tumors in mice remain the method of choice. Xenografts of LNCaP human prostate carcinoma cells have been used to address tumorigenesis of an androgen sensitive prostate carcinoma in many previous studies (15, 16, 17) . The purpose of the present study was to assess the differential effects of several human prostate stromal cell lines initiated by our laboratory on early tumorigenesis events in LNCaP xenografts in a nude mouse model system. Specifically, tumor incidence, tumor growth, and angiogenesis were evaluated under different xenograft conditions. We report here that LNCaP tumor incidence and rate of tumor growth was dependent on the stromal cell conditions used, and that tumor-promoting stromal cells were associated with early and elevated angiogenesis. Furthermore, these studies show the development of a modular DRS LNCaP xenograft model system that exhibits a 100% tumor incidence, tumor homogeneity, early angiogenesis, and regulated transgene expression in the stromal cell population of the tumor.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Human prostate stromal cell lines were established according to our protocol published previously (18
, 19)
. Briefly, fresh tissue cores were obtained from the Baylor College of Medicine Prostate Specialized Program of Research Excellence Pathology and Tissue Microarray Core. Tissues originated from organ donors or patients undergoing radical prostatectomy. Unless noted, tissue cores were isolated from regions of normal prostate, based on histopathological criteria. The cores were diced into 1-mm cubes, washed with HBSS, and put into 24-well tissue culture plates containing Bfs medium: DMEM (Life Technologies, Inc., Rockville, MD) supplemented with 5% fetal bovine serum, 5% Nu Serum (Collaborative Research, Bedford, MA), 0.5 µg/ml testosterone, 5 µg/ml insulin, 100 units/ml penicillin, and 100 µg/ml streptomycin (Sigma, St. Louis, MO). The explants were incubated at 37°C with 5% CO2, and culture medium was changed every 48 h. Stromal cells migrated out of the tissue and attached to the culture dish. After the cells reached confluence, the remaining tissue was removed, and the cells were passaged using standard trypsin/EDTA procedures. The following stromal cell lines were generated: HTS-40C (transition zone of a 40-year-old), HPS-40F (peripheral zone of a 40-year-old), HPS-44D (peripheral zone of a 44-year-old), HTS-2T (transition zone of a 16-year-old organ donor), and HPS-TZ1A (transition zone of benign prostatic hyperplasia specimen). Standard immunocytochemistry procedures were used to evaluate cell phenotype. Cytokeratin expression was not detected with the AE1/AE3 pooled monoclonal antibody (Boehringer Mannheim, Indianapolis, IN), and all cell lines were 100% vimentin positive (sc-7557; Santa Cruz Biotechnology, Santa Cruz, CA). Expression of sm 
-actin (clone 1A4; Sigma) varied among stromal cell lines, from no expression (HPS-TZ1A) to approximately 50% of the population (HTS-40C) to nearly 100% (HTS-2T). Cultures at passages 5–15 were used for experiments.
The GeneSwitch System (Invitrogen, Carlsbad, CA), a mifepristone-regulated expression system for mammalian cells, was used to create a stromal cell line with regulated expression of the lacZ gene. The GeneSwitch-3T3 fibroblast line, which expresses the GeneSwitch regulatory protein from the pSwitch vector, was cultured in DMEM supplemented with 10% fetal bovine serum and 50 µg/ml hygromycin B (Invitrogen, Carlsbad, CA). This cell line was transfected with the pGENE/V5-His/lacZ vector (Invitrogen) using FuGENE 6 transfection reagent according to manufacturer’s recommendations (Roche, Indianapolis, IN). Stably transfected cells were selected with 300 µg/ml Zeocin (Invitrogen). Zeocin-resistant clones were treated with 100 pM mifepristone (Sigma) and screened for ß-gal expression using standard in vitro X-gal staining procedures. The GeneSwitch-3T3-pGene/lacZ cell line used in this study represents a pooled population of stably transfected cells.
Animals.
Athymic NCr-nu/nu male homozygous nude mice, 6–8 weeks of age, were purchased from Charles River Laboratories (Wilmington, MA). All experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
Preparation of LNCaP Xenografts.
Xenograft tumors were generated under different stromal conditions: one-way xenografts (LNCaP cells, stromal cells, or Matrigel ECM only); two-way xenografts (LNCaP + Matrigel, LNCaP + stromal cells, or stromal cells + Matrigel); and three-way xenografts (LNCaP cells + stromal cells + Matrigel). LNCaP cells and stromal cells were harvested from culture plates by trypsinization, resuspended in growth medium, and counted with a hemacytometer. Cells were used immediately or frozen in aliquots for modular xenograft experiments. For frozen aliquots, cells were pelleted at 
950 x g for 50 s in a clinical centrifuge (IEC model CL with rotor 809, setting 5), resuspended in filtered freezing medium (culture medium + 10% DMSO), and transferred to cryogenic vials (Corning Inc., Corning, NY). Cells were frozen using a StrataCooler Cryo preservation module (Stratagene, La Jolla, CA) and stored at -80°C. Matrigel ECM (Becton Dickinson, Bedford, MA) was stored in 0.5-ml aliquots at -20°C and then thawed on ice at 4°C for 3 h before use.
For modular three-way xenograft experiments, frozen aliquots of cells (16 x 106 LNCaP cells and 4 x 106 stromal cells) were thawed in a 37°C water bath for 1–2 min, transferred to separate 15-ml conical tubes, washed with 10 ml of culture medium, and pelleted as described above. LNCaP cells were resuspended in 10 ml of culture medium, whereas stromal cells were resuspended in 3 ml of culture medium. Then, cells were combined in one tube and pelleted again. The supernatant was aspirated to the 300-µl mark, and cells were gently resuspended in the remaining medium. Before combining with Matrigel, cells were incubated on ice for 5 min. A prechilled pipette was used to transfer cells to the tube containing 0.5 ml of Matrigel (on ice). Cells were mixed with the Matrigel and then drawn into a prechilled pipette 1-ml syringe with a 20-gauge needle. Using a 25-gauge needle, 100 µl of cell suspension (2 x 106 LNCaP cells and 0.5 x 106 stromal cells, 4:1 ratio) were injected s.c. in each lateral flank. Three animals (6 total injection sites) were used for each experiment set.
For LNCaP/stromal cell two-way xenograft experiments, 16 x 106 LNCaP cells and 8 x 106 stromal cells were washed, combined, and resuspended as described above. The cells were mixed with 500 µl of PBS instead of Matrigel, and 100 µl of cell suspension (2 x 106 LNCaP cells and 1 x 106 stromal cells, 2:1 ratio) were injected s.c. in each lateral flank. For LNCaP/Matrigel two-way xenograft experiments, 16 x 106 LNCaP cells were washed twice with 10 ml of culture medium, resuspended in 300 µl of medium, incubated on ice, mixed with 0.5 ml of Matrigel, and injected s.c., as described above. For one-way xenograft experiments, 16 x 106 LNCaP cells or 8 x 106 stromal cells were washed, resuspended in 300 µl of medium, mixed with 500 µl of PBS, and injected s.c. as described above.
To induce expression of the lacZ reporter gene in GeneSwitch-3T3-pGene/lacZ cells, animals received mifepristone (RU 486; Sigma) at 0.3 mg/kg administered as 100-µl i.p. injections. Animal dosage of mifepristone was based on protocols shown previously to induce gene expression in vivo (20 , 21) . Treatment began at the time of experimental setup and was repeated every 48 h. Mifepristone was dissolved in ethanol (2 mg/ml) and then diluted in sesame oil (Sigma) to the appropriate concentration. For vehicle control, animals were treated with ethanol diluted in sesame oil.
Processing of Tumors.
Animals were monitored daily, and tumors were harvested at time points ranging from 4 days to 9 weeks, depending on the parameter being evaluated. Tumor volume was not allowed to exceed 150 mm3
. Tumors visible with the naked eye were surgically removed and dissected away from surrounding skin and fascia. Tumors were measured in three dimensions with calipers, and tumor volume (mm3
) was calculated with the formula V = 0.52 x length x width x height (22)
. Tumors were then transferred to preweighed tubes on ice. Tubes were reweighed, and tumor weight (g) was determined. Tissues were fixed in 4% paraformaldehyde overnight at 4°C and then washed 3x with PBS and processed for histology. Tissues were embedded in paraffin, and 5-µm sections were cut and mounted onto ProbeOn Plus slides (Fisher Scientific, Pittsburgh, PA). Sections were stained with H&E and Masson’s Trichrome (Sigma) for histological analysis.
Immunohistochemistry and in Situ Hybridization.
Antibodies used were: sm -actin, mouse monoclonal 1A4 (Sigma); antimouse CD31/PECAM-1, rat monoclonal MEC13.3 (BD PharMingen, San Diego, CA); biotin-conjugated Universal Secondary (Research Genetics, Huntsville, AL) used for sm--actin; and biotin-conjugated goat antirat IgG (BD PharMingen) used for CD31. Specificity of each primary antibody has been evaluated and published previously. No significant staining was observed if sections were incubated with secondary antibody only.
Immunostaining was performed with the MicroProbe Staining System (FisherBiotech, Pittsburgh, PA). Reagents formulated for use with capillary action systems were purchased from Research Genetics (Huntsville, AL) and used according to the manufacturer’s protocol. Tissues were deparaffinized using Auto Dewaxer and cleared with Auto Alcohol. Brigati’s Iodine and Auto Prep were used to improve tissue antigenicity. Then, sections were washed with Universal Buffer. For sm -actin staining, sections were incubated in 20 µg/ml goat-antimouse Fab fragment (Jackson ImmunoResearch, West Grove, PA) for 30 min at 37°C to block host immunoglobulins. For CD31 staining, antigen retrieval was required; tissues were incubated in 0.1% trypsin (Zymed, South San Francisco, CA) for 10 min at 37°C. After these treatments, sections were washed with Universal Buffer, incubated in Protein Blocker, and washed again. Antibodies were diluted in Primary Antibody Diluent and used at the following conditions: sm -actin, 1:200 for 8 min at 50°C; and CD31, 1:50 overnight at 4°C. Tissues were washed with Universal Buffer and incubated in secondary antibody: Universal Secondary undiluted for 4 min at 50°C; and antirat IgG 1:100 for 45 min at 37°C. Tissues were washed in Universal Buffer, treated with Auto Blocker to inhibit endogenous peroxidase activity, and washed again. For detection, sections were incubated in streptavidin horseradish peroxidase (sm -actin) or RTU VectaStain Elite ABC reagent (Vector Laboratories, Burlingame, CA; CD31), washed in Universal Buffer and then incubated in stable diaminobenzidine tetrahydrochloride two times for 3 min each at 50°C. Tissues were counterstained with Auto Hematoxylin for 30 s.
In situ hybridization to specifically label human cells was performed with the MicroProbe Staining System according to a procedure published previously (23) . All reagents were purchased from Research Genetics and used according to the manufacturer’s protocol. Tissue sections were deparaffinized in xylene and then rehydrated in 100, 95, and 70% ethanol, followed by double-distilled H2O. Slides were incubated in Auto Blocker for 1 min at room temperature and washed three times with Universal Buffer. Tissues were treated with pepsin for 1 min at 105°C, and then Alu1/Alu2 probe was added (prediluted and used at 1 µg/ml). Tissues were incubated in Alu1/Alu2 probe for 5 min at 105°C and then at 45°C for 1.5 h. Sections were washed with Post Hybe Wash for 5 min at 45°C and incubated in streptavidin horseradish peroxidase for 10 min at 50°C. After incubation in Probe Lock for 10 s at room temperature, tissues were treated with stable diaminobenzidine tetrahydrochloride, rinsed with Auto Wash, and counterstained with Auto Hematoxylin as described above.
Microvessel Density Analysis.
Analysis was performed according to standard procedures (24)
. Tissue sections were stained for CD31 as described above. Sections were scanned at x200, and areas with the highest vascular density were identified. Vessels in three high-power fields (x400) were counted by two independent observers, one of whom was blinded to experimental conditions. The average vessel count was determined for each specimen. Six tumors from each condition were analyzed, and counts were combined for statistical analysis by unpaired t test.
Hemoglobin Assay.
Hemoglobin content was measured using Drabkin’s method (25)
. Whole tumors were homogenized in 50 µl of double-distilled H2O using disposable pellet pestles for microtubes (Fisher Scientific). Homogenates were incubated in 0.5 ml of Drabkin’s Solution (Sigma) for 15 min at room temperature. Samples were centrifuged to pellet cell debris. The supernatants were transferred to cuvettes, and the absorbance was measured at 540 nm. Drabkin’s Solution was used as a blank. The absorption, which is proportional to the total hemoglobin concentration, was divided by tumor weight. Six tumors from each condition were assayed, and measurements were combined for statistical analysis by unpaired t test.
Whole-Mount ß-gal Staining.
Whole tumors were stained according to standard procedures. Briefly, tumors were harvested at day 10 and fixed with 2% paraformaldehyde/0.2% glutaraldehyde (Polysciences, Inc., Warrington, PA) in PBS for 30 min at 4°C on a platform rocker. Tissues were washed three times for 30 min each at room temperature with rocking in ß-gal wash buffer [0.1 M sodium phosphate buffer (pH 7.4), 2 mM MgCl2, 0.01% sodium deoxycholate, and 0.02% NP40]. Then, tumors were incubated at 37°C for 3 h in ß-gal staining solution [ß-gal wash buffer + 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, and 1 mg/ml X-gal (Promega, Madison, WI)]. Tissues were washed three times for 30 min each in PBS at room temperature with rocking. Tumors were postfixed in 4% paraformaldehyde overnight at 4°C and washed three times with PBS. Whole tumors were photographed with a Leica GZ6 stereomicroscope, and then tissues were embedded in paraffin and sectioned. Thin sections were counterstained with nuclear fast red.
Statistical Analysis.
Incidence of tumor formation between two experimental conditions was analyzed by Fisher’s exact test, whereas multiple conditions were compared with the 
2 test. Tumor weight, tumor volume, microvessel density, and hemoglobin content were each evaluated with an unpaired t test. Analysis was performed with GraphPad Prism for Macintosh version 3.0 (GraphPad Software, San Diego, CA). P < 0.05 was considered statistically significant.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-actin. Thus, the stromal cell lines represented a mix of fibroblasts and myofibroblasts, which are the cell phenotypes observed in human prostate cancer reactive stroma.4
For tumor incidence studies, the growth period ranged from 2 to 9 weeks, and tumors were harvested at different time points for histological analysis. A tumor was defined as a palpable mass that contained nodules of LNCaP carcinoma cells upon histological examination. Inoculation of nude mice with LNCaP cells alone (one-way control xenografts) resulted in a low incidence of tumor formation (8%; Fig. 1
, Column a), which is consistent with previous reports (28
, 29)
. After 9 weeks, the human prostate stromal cell lines did not form palpable masses when injected alone (Fig. 1
, Columns b–d) or when injected with Matrigel (data not shown). Thus, under one-way xenograft conditions, the LNCaP carcinoma cells were only weakly tumorigenic, whereas the human prostate stromal cells were nontumorigenic.
|
, Column e) increased tumor incidence to 63% (P < 0.001, Fisher’s exact test). Throughout this report, standard LNCaP/Matrigel xenografts (L/M) were used as a positive control by which to examine the effect of stromal cells on LNCaP tumorigenesis. Coinjection of human prostate stromal cells with LNCaP cells in two-way xenograft experiments (L/S) differentially regulated the incidence of LNCaP tumor formation. Three independent prostate stromal cell lines (HTS-40C, HPS-40F, and HPS-TZ1A) promoted growth of LNCaP tumors in at least 50% of injection sites (Fig. 1
, Columns f–h), whereas two other stromal cell lines (HTS-2T and HPS-44D) did not support LNCaP tumorigenesis (0% tumor incidence at 9 weeks after inoculation; Fig. 1
, Columns i–j). Compared with injection of LNCaP cells alone, the increase in tumor incidence attributable to coinjection of LNCaP cells with HTS-40C, HPS-40F, or HPS-TZ1A stromal cells was statistically significant (P = 0.003, 0.009, 0.003, respectively, Fisher’s exact test). Moreover, there was no significant difference in the incidence of LNCaP tumor formation with these stromal cell lines as compared with Matrigel. In addition, there were no obvious differences in the rate of tumor growth between L/M and tumorigenic L/S xenografts.
Combining LNCaP cells with both Matrigel and human prostate stromal cells (three-way L/M/S xenografts) further elevated LNCaP tumor incidence to 100% (Fig. 1
, Columns k–l). Relative to tumor incidence in two-way xenografts, the increased tumor incidence in three-way conditions was statistically significant (P < 0.001, 2 test). Interestingly, HTS-2T normal human prostate stromal cells promoted LNCaP tumor growth in three-way xenografts but not in two-way xenografts (P < 0.001, Fisher’s exact test). These data show that the stromal microenvironment, including both the stromal cells and the ECM, is a critical regulator of LNCaP tumorigenesis.
Analysis of Two-way Xenograft Tumors.
Histological examination revealed dramatic differences in the morphology of control 2-way LNCaP/Matrigel (L/M) tumors as compared with two-way LNCaP/stromal cell (L/S) tumors. At early time points (2 weeks), control L/M tumors consisted of small clusters of LNCaP cells embedded in Matrigel (Fig. 2A)
. Invasion of mouse host stromal cells into the Matrigel was also observed (Fig. 2A
, asterisk). Similar to observations by Gao et al. (31)
, the stromal cells did not form a collar of smooth muscle around the clusters of carcinoma cells. In contrast to L/M tumors, the histological appearance of early L/S tumors was more typical of the epithelial-stromal architecture observed in human prostate carcinoma. Masson’s trichrome staining showed that nodules of LNCaP cells were surrounded by a stroma rich in collagen fibers and blood vessels (Fig. 2C)
. Thus, the stroma in two-way L/S tumors exhibited features more consistent with human prostate cancer reactive stroma, which we have described previously (4)
.4
Additionally, the LNCaP nodules were more extensive in two-way L/S tumors relative to two-way control L/M tumors. These data suggest that human prostate stromal cells may confer a growth/survival advantage to LNCaP cells and thus enhance LNCaP tumorigenesis.
|
. However, although connective tissue septa in L/S tumors contained blood vessels (Fig. 2G,
arrows), control L/M tumors appeared to lack normal vasculature. Rather, the L/M tumors were hemorrhagic, and large pools of RBCs, previously termed "blood lakes" (32)
, were observed frequently (Fig. 2E
, asterisk).
To examine the vasculature in two-way xenograft tumors, we performed immunohistochemistry with an antibody to CD31 (PECAM-1), an endothelial cell marker. CD31 immunostaining was rarely detected in control L/M tumors at 2 weeks (Fig. 2B)
, which is consistent with the lack of blood vessels observed by H&E or Masson’s Trichrome stain. In contrast, numerous CD31-positive vessels were present in the stromal compartment of early (2 weeks) L/S tumors (Fig. 2D)
. Moreover, sm -actin-positive mural cells (pericytes or smooth muscle cells) surrounded these blood vessels, indicating that vessels were mature (data not shown; Ref. 33
). Although some CD31-positive vessels were observed in late-stage L/M tumors (Fig. 2F
, arrow), most RBCs appeared to be in blood lakes, which were CD31 negative (Fig. 2F
, asterisk). Late-stage L/S tumors were well vascularized, and vessels were positive for both CD31 (data not shown) and sm -actin (Fig. 2H)
. Analysis of two-way xenograft tumors suggests that stromal cells influence LNCaP tumor development and vascularization, particularly during early tumorigenesis.
Analysis of Three-Way Xenograft Tumors.
Comparison of two-way control L/M tumors with three-way L/M/S tumors allowed a more direct evaluation of the role of stromal cells in LNCaP tumorigenesis. As shown above, coinjection of stromal cells with LNCaP cells and Matrigel significantly increased tumor incidence relative to two-way conditions (Fig. 1)
. Moreover, three-way L/M/S tumors exhibited a 47% increase in wet weight compared with two-way L/M tumors at day 10 (Fig. 3A
; P = 0.009, unpaired t test). A significant difference in tumor volume was not observed at day 10 (Fig. 3B)
; however, the tumors appeared very different. Control L/M tumors at day 10 were translucent, whereas three-way L/M/S tumors were opaque with blood vessels visible on the tumor surface (Fig. 4A)
. Histological examination of three-way tumors at day 10 revealed large clusters of LNCaP cells with adjacent stromal cells and numerous blood vessels embedded in Matrigel (Fig. 4, B and C)
. In contrast, L/M tumors consisted of small clusters of LNCaP cells with little vascularization, similar to tumors harvested at 2 weeks (Fig. 2, A and B)
. In situ hybridization with a human-specific probe showed that three-way L/M/S tumor stroma was composed of human prostate stromal cells (Fig. 4D
, arrows) mixed with mouse host stromal cells. The stromal cells were frequently adjacent to clusters of LNCaP cells, similar to the histological architecture of human prostate cancer. These stromal cells were sm -actin positive, which is consistent with the myofibroblast phenotype (Fig. 5B
, arrowheads). In addition, staining with Masson’s trichrome showed that stromal cells adjacent to carcinoma cells and blood vessels were producing collagen matrix (Fig. 4C
, arrow).
|
|
|
. The wet weight (Fig. 3A)
of three-way L/M/S tumors was significantly higher than two-way control L/M tumors at the day 21 time point (64% increase; P < 0.001, unpaired t test). Moreover, at this same time point, the three-way tumors exhibited a 2.4-fold increase in tumor volume compared with two-way L/M tumors (Fig. 3B
; P < 0.001, unpaired t test). Histological analysis of L/M tumors at day 21 revealed considerable heterogeneity. Sheets or large clusters of LNCaP cells were observed in some regions (Fig. 4G)
, whereas other areas of the two-way L/M tumors exhibited small clusters of LNCaP cells, similar to day 10 (Fig. 4F)
. It was noted that regions with increased LNCaP cell density contained blood vessels (Fig. 4G
, arrow), although some blood lakes had also formed (Fig. 4G
, asterisk). Neither the average wet weight (Fig. 3A)
nor the volume (Fig. 3B)
of two-way control L/M tumors exhibited statistically significant differences between days 10 and 21 (P = 0.2 and 0.8, respectively, unpaired t test). Together, these data show that stromal cells increase LNCaP tumor incidence and accelerate the rate of LNCaP tumor growth.
Angiogenesis in Three-Way L/M/S Tumors.
To investigate the vasculature in early three-way L/M/S tumors, we examined tissues harvested 4, 7, and 10 days after injection. Blood vessels were not observed in H&E-stained tissue sections at day 4. However, vessels were typically observed in day 7 tumors, and tumors were well vascularized by day 10 with no evidence of blood lakes. Vessels were lined with CD31-positive endothelial cells (Fig. 5A)
and surrounded by sm -actin-positive mural cells (Fig. 5B
, arrows). Thus, vascularization of early three-way L/M/S tumors was attributable to the development of mature blood vessels, not blood lakes.
Microvessel density and hemoglobin content were measured to quantitate the vascularity in control L/M tumors and in L/M/S tumors. Microvessel density analysis was performed on CD31-stained tissue sections. The average microvessel count per x400 field in three-way tumors at day 10 was 31 ± 5 (Fig. 6A
, Column b). In contrast, the average microvessel count of early two-way control L/M tumors was 3 ± 2 (Fig. 6A
, Column a). The 10.3-fold increase in vascularization of three-way L/M/S tumors was statistically significant (P < 0.001, unpaired t test). In addition, two-way L/M tumors and three-way DRS tumors harvested at day 10 were assayed for hemoglobin content by Drabkin’s method. The concentration of hemoglobin, normalized to tumor weight, in three-way L/M/S tumors was 2-fold higher than in control L/M tumors (Fig. 6B
; P = 0.004, unpaired t test). These data show that the accelerated LNCaP tumorigenesis observed in three-way xenografts with stromal cells, relative to two-way xenografts with Matrigel only, correlates with elevated microvessel density and hemoglobin content in early tumors. Moreover, these data suggest that stromal cells enhance LNCaP tumorigenesis by promoting angiogenesis.
|
, Column n). In addition, tumor size, morphology, and vascularity at day 10 were similar to three-way tumors generated with LNCaP cells and human prostate stromal cells. Animals were treated with vehicle control or with mifepristone (RU 486) to induce expression of the lacZ reporter gene. No statistically significant differences in weight or volume were observed between vehicle control and mifepristone-treated tumors (data not shown). Tumors harvested from animals treated with vehicle control did not exhibit detectable ß-gal activity in whole tissues (Fig. 7A)
or in tissue sections (Fig. 7C)
. In contrast, mifepristone induced expression of the lacZ gene in LNCaP/3T3-pGene/lacZ tumors, as shown by the high level of X-gal staining (Fig. 7B)
. Examination of tissue sections revealed that ß-gal activity was restricted to stromal cells (Fig. 7, D and E)
. Moreover, positive staining stromal cells were frequently adjacent to clusters of LNCaP cells (Fig. 7D
, arrows), which is consistent with the tissue architecture of other three-way L/M/S tumors (Fig. 4D)
. Significantly, stromal cells expressing ß-gal were also observed surrounding blood vessels in a mural cell (pericyte) position in the vessel wall (Fig. 7E
, arrows). To our knowledge, this is the first study to show regulated stromal cell gene expression in an in vivo cancer model. Furthermore, these data suggest a direct interaction between inoculated stromal cells and the developing vasculature.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Our data demonstrate that the stromal effect on LNCaP tumorigenesis is differential, in that not all human prostate stromal cell lines were tumor promoting in two-way combinations. Moreover, under two-way xenograft conditions, the incidence of tumor formation did not exceed 63%. The results of the three-way experiments show that a more complete stromal microenvironment was required to reach maximal tumor incidence, accelerated tumor growth, and more homogeneous tumors. The three-way combinations represented a more complete tumor model in that all three critical components are supplied: tumor cells, stromal cells, and a stromal cell-derived matrix. Of most significance, this three-way mix results in a tumor with stimulated angiogenesis during early tumor formation.
It is clear that the appropriate rate and extent of angiogenesis is a critical component of cancer progression (34, 35, 36) . The mechanisms through which stromal cells promote angiogenesis in our model are not yet understood; however, stromal cells may affect angiogenesis at several levels. Stromal cells may stimulate host endothelial cell migration into the xenograft as well as promote the subsequent formation of endothelial tubes. Indeed, growth factors such as vascular endothelial growth factor and fibroblast growth factor-2, known to be important for endothelial migration and tube formation, are secreted by stromal cells (37 , 38) . Moreover, deposition of specific ECM components by stromal cells may regulate endothelial cell response to angiogenic factors (39) . It has also been shown that stromal cells directly promote vessel maturation by cell-cell interactions. Endothelial cells recruit adjacent stromal cells as mural cells destined to become pericytes or smooth muscle cells (33) . This endothelial cell-mural cell interaction functions to stabilize the developing vessel (33) . It has been shown that nascent endothelial cell tubes are unstable and regress in the absence of perivascular stromal cells if vascular endothelial growth factor is withdrawn (40) . Accordingly, in addition to stimulating the process of angiogenesis, stromal cells are an integral component of the mature vessel wall and are required for vessel function. Indeed, our data with lacZ-positive stromal cells show a close association of these cells with endothelial tubes, in a mural cell position. It is likely that the human stromal cells are also incorporated into vessel walls, although they were not readily observed in tissue sections stained with a human-specific probe. The chromosome in situ hybridization technique does not label stromal cells with the same intensity as epithelial cells, and stromal cells in vessel walls are attenuated in cross section. Thus, chromosome in situ hybridization may not be sufficient to identify human stromal cells in the vessel wall.
Nonstromal L/M control tumors at early time points showed essentially no vessel development and exhibited blood lakes at later time points. The blood lakes were not lined by CD31-positive endothelial cells or sm -actin-positive mural cells. This is consistent with data reported by Wilson and Sinha (41)
, where LNCaP-Matrigel tumors exhibited "large dilated blood vessels" that were negative for von Willebrand factor, an endothelial marker. Our results suggest that the subsequent formation of blood lakes in two-way L/M tumors functions to compensate for lack of adequate vascularization attributable to the absence of stromal cells in early tumors. In contrast, our three-way L/M/S tumors exhibited normal-appearing vessels as early as day 7 and were well vascularized with mature vessels by day 10 after inoculation. Accordingly, the pattern and type of vascularization in two-way and three-way LNCaP xenograft tumors appear to be dependent on the presence of stromal cells.
Precancerous PIN lesions in the human prostate gland induce phenotypic changes in the immediate stroma, characterized by activation of stromal cells and stimulation of matrix remodeling (42) .4 Increased microvessel density in the stroma adjacent to PIN lesions has also been reported (11 , 12) . This suggests that early events in epithelial transformation act to induce reactive stroma, which in turn stimulates angiogenesis required for further progression of the precancerous lesion. Indeed, the preponderance of data now indicate that angiogenic switches occur early in the premalignant stages of most carcinomas (43 , 44) . Our data suggest that the induction of a reactive stroma in developing cancer with the resulting angiogenic switch is an important and probably required step in successful tumorigenesis.
Although our studies have addressed angiogenesis, stromal cells are likely to provide paracrine-acting growth factors as well as structural and regulatory ECM components that directly affect LNCaP cell survival and growth. Accordingly, the stromal microenvironment likely regulates tumorigenesis through several mechanisms. Indeed, coculture of prostate carcinoma-associated fibroblasts with transformed prostate epithelial cells resulted in increased proliferation and reduced apoptosis of the epithelial cells (10) . Again, these observations suggest that the three-way xenograft approach is a more complete tumor model.
We have termed the experimental approach reported here as the DRS xenograft model. The model has been useful to address the role of the stromal microenvironment in tumorigenesis. Furthermore, we have extended the utility of the model by showing the regulated expression of a transgene in the stromal cells of an experimental carcinoma xenograft. The DRS model system will allow for the direct testing of stromal cell gene products in regulating carcinoma tumorigenesis. This approach will be valuable in dissecting specific mechanisms of stromal-epithelial interactions in prostate cancer. Of particular value was the finding that this system was efficient in regulation of transgene expression. Expression was stimulated in response to mifepristone; however, it was undetectable in vehicle control-treated animals. In addition, the model is based on the use of frozen cell aliquots (epithelial and stromal cells) for establishing the xenograft. The use of frozen cell aliquots as opposed to passaging cells from growing cultures greatly increased throughput and homogeneity of xenograft experiments. Combined with the use of engineered stromal cells, this provides for a modular approach. We anticipate being able to combine carcinoma cells with differentially transfected stromal cells, all derived from an initial pSwitch transfectant cell line. The advancement of regulated stromal gene expression in the DRS xenograft tumor model is significant because promoters do not currently exist for targeting gene expression to the stromal compartment of a transgenic animal in a tissue-specific manner. Moreover, regulatable expression with the GeneSwitch system will allow for expression of a transgene at any time point during tumorigenesis. One potential caveat of the DRS model in its current form is the use of 3T3 cells as an engineered stromal cell source. For the specific questions asked in this study, use of 3T3 cells has been suitable for examination of early events; however, 3T3 cells are tumorigenic and can form sarcomas with time in nude mice. Accordingly, we are establishing GeneSwitch transfectants of prostate stromal cell lines derived from C57/BL6 mice for use in further studies with human carcinoma cells in nude mice and with TRAMP carcinoma cells (45) in syngeneic C57/BL6 hosts.
The studies presented here represent an advancement in the understanding of stroma-regulated events in early tumorigenesis, particularly in the regulation of angiogenesis. Furthermore, these studies have led to the development of a modular and rapid DRS xenograft model system, which will be useful in evaluating the biological function of differential gene expression in the stromal compartment of cancer. It is becoming more clear that the stromal compartment is important to tumor development and progression. It follows that the development of prognostic markers and therapeutic targets in the stromal compartment is a distinct possibility in the future.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 This work was supported by NIH Grants RO1-CA58093, RO1-DK45909, Specialized Program of Research Excellence CA58204, and UO1-CA84296. S. J. M. is a Hudson Scholar of the Baylor College of Medicine Medical Scientist Training Program. 
2 To whom requests for reprints should be addressed, at Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030. Phone: (713) 798-6220; Fax: (713) 790-1275; E-mail: drowley{at}bcm.tmc.edu.
3 The abbreviations used are: ECM, extracellular matrix; PIN, prostatic intraepithelial neoplasia; DRS, differential reactive stroma; sm -actin, smooth muscle -actin; ß-gal, ß-galactosidase; X-gal, 5-bromo-4-chloro-3-indoyl-ß-D-galactopyranoside; DAB, diaminobenzidine tetrahydrochloride; L/M, LNCaP/Matrigel (two-way xenografts); L/S, LNCaP/stromal cell (two-way xenografts); L/M/S, LNCaP/Matrigel/stromal cell (three-way xenografts).
4 J. A. Tuxhorn, G. E. Ayala, V. C. Smith, T. D. Dang, and D. R. Rowley. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and ECM remodeling, submitted for publication.
Received 12/21/01. Accepted 3/27/02.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  O. Dakhova, M. Ozen, C. J. Creighton, R. Li, G. Ayala, D. Rowley, and M. Ittmann Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer Clin. Cancer Res., June 15, 2009; 15(12): 3979 - 3989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ishii, T. Imamura, K. Iguchi, S. Arase, Y. Yoshio, K. Arima, K. Hirano, and Y. Sugimura Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo Endocr. Relat. Cancer, June 1, 2009; 16(2): 415 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Augsten, C. Hagglof, E. Olsson, C. Stolz, P. Tsagozis, T. Levchenko, M. J. Frederick, A. Borg, P. Micke, L. Egevad, et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth PNAS, March 3, 2009; 106(9): 3414 - 3419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Hwang, T. Moore, T. Arumugam, V. Ramachandran, K. D. Amos, A. Rivera, B. Ji, D. B. Evans, and C. D. Logsdon Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression Cancer Res., February 1, 2008; 68(3): 918 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Granot, Y. Addadi, V. Kalchenko, A. Harmelin, L. A. Kunz-Schughart, and M. Neeman In vivo Imaging of the Systemic Recruitment of Fibroblasts to the Angiogenic Rim of Ovarian Carcinoma Tumors Cancer Res., October 1, 2007; 67(19): 9180 - 9189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ricciardelli, D. L. Russell, M. P. Ween, K. Mayne, S. Suwiwat, S. Byers, V. R. Marshall, W. D. Tilley, and D. J. Horsfall Formation of Hyaluronan- and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility J. Biol. Chem., April 6, 2007; 282(14): 10814 - 10825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bruno, B. Bussolati, C. Grange, F. Collino, M. E. Graziano, U. Ferrando, and G. Camussi CD133+ Renal Progenitor Cells Contribute to Tumor Angiogenesis Am. J. Pathol., December 1, 2006; 169(6): 2223 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty and K. I. Block Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268. [Abstract] [PDF]
|
|
|
|
|
|
M. L. Cher, D. A. Towler, S. Rafii, D. Rowley, H. J. Donahue, E. Keller, M. Herlyn, E. A. Cho, and L. W.K. Chung Cancer Interaction with the Bone Microenvironment: A Workshop of the National Institutes of Health Tumor Microenvironment Study Section Am. J. Pathol., May 1, 2006; 168(5): 1405 - 1412. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hanson, J. W. Gillespie, A. Grover, M. A. Tangrea, R. F. Chuaqui, M. R. Emmert-Buck, J. A. Tangrea, S. K. Libutti, W. M. Linehan, and K. G. Woodson Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst, February 15, 2006; 98(4): 255 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rennebeck, M. Martelli, and N. Kyprianou Anoikis and Survival Connections in the Tumor Microenvironment: Is There a Role in Prostate Cancer Metastasis? Cancer Res., December 15, 2005; 65(24): 11230 - 11235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Uemura, H. Ishiguro, Y. Nagashima, T. Sasaki, N. Nakaigawa, H. Hasumi, S. Kato, and Y. Kubota Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells Mol. Cancer Ther., November 1, 2005; 4(11): 1699 - 1709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Galie, C. Sorrentino, M. Montani, L. Micossi, E. Di Carlo, T. D'Antuono, L. Calderan, P. Marzola, D. Benati, F. Merigo, et al. Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells Carcinogenesis, November 1, 2005; 26(11): 1868 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Yang, J. A. Tuxhorn, S. J. Ressler, S. J. McAlhany, T. D. Dang, and D. R. Rowley Stromal Expression of Connective Tissue Growth Factor Promotes Angiogenesis and Prostate Cancer Tumorigenesis Cancer Res., October 1, 2005; 65(19): 8887 - 8895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hagisawa, C. Ohyama, T. Takahashi, M. Endoh, T. Moriya, J. Nakayama, Y. Arai, and M. Fukuda Expression of core 2 {beta}1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression Glycobiology, October 1, 2005; 15(10): 1016 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yang, C. Zhong, B. Frenkel, A. H. Reddi, and P. Roy-Burman Diverse Biological Effect and Smad Signaling of Bone Morphogenetic Protein 7 in Prostate Tumor Cells Cancer Res., July 1, 2005; 65(13): 5769 - 5777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kiaris, I. Chatzistamou, G. Trimis, M. Frangou-Plemmenou, A. Pafiti-Kondi, and A. Kalofoutis Evidence for Nonautonomous Effect of p53 Tumor Suppressor in Carcinogenesis Cancer Res., March 1, 2005; 65(5): 1627 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Crescioli, A. Morelli, L. Adorini, P. Ferruzzi, M. Luconi, G. B. Vannelli, M. Marini, S. Gelmini, B. Fibbi, S. Donati, et al. Human Bladder as a Novel Target for Vitamin D Receptor Ligands J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 962 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Sis, S Sarioglu, S Sokmen, M Sakar, A Kupelioglu, and M Fuzun Desmoplasia measured by computer assisted image analysis: an independent prognostic marker in colorectal carcinoma J. Clin. Pathol., January 1, 2005; 58(1): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sivashanmugam, L. Tang, and Y. Daaka Interleukin 6 Mediates the Lysophosphatidic Acid-regulated Cross-talk between Stromal and Epithelial Prostate Cancer Cells J. Biol. Chem., May 14, 2004; 279(20): 21154 - 21159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Gray, W. J. Huss, J. M. Yau, L. E. Durham, E. S. Werdin, W. K. Funkhouser Jr., and G. J. Smith Short-Term Human Prostate Primary Xenografts: An in Vivo Model of Human Prostate Cancer Vasculature and Angiogenesis Cancer Res., March 1, 2004; 64(5): 1712 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Walter-Yohrling, X. Cao, M. Callahan, W. Weber, S. Morgenbesser, S. L. Madden, C. Wang, and B. A. Teicher Identification of Genes Expressed in Malignant Cells That Promote Invasion Cancer Res., December 15, 2003; 63(24): 8939 - 8947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ayala, J. A. Tuxhorn, T. M. Wheeler, A. Frolov, P. T. Scardino, M. Ohori, M. Wheeler, J. Spitler, and D. R. Rowley Reactive Stroma as a Predictor of Biochemical-Free Recurrence in Prostate Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4792 - 4801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. McAlhany, S. J. Ressler, M. Larsen, J. A. Tuxhorn, F. Yang, T. D. Dang, and D. R. Rowley Promotion of Angiogenesis by ps20 in the Differential Reactive Stroma Prostate Cancer Xenograft Model Cancer Res., September 15, 2003; 63(18): 5859 - 5865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Chauhan, A Abraham, J R A Phillips, J H Pringle, R A Walker, and J L Jones There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions J. Clin. Pathol., April 1, 2003; 56(4): 271 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tuxhorn, S. J. McAlhany, F. Yang, T. D. Dang, and D. R. Rowley Inhibition of Transforming Growth Factor-{beta} Activity Decreases Angiogenesis in a Human Prostate Cancer-reactive Stroma Xenograft Model Cancer Res., November 1, 2002; 62(21): 6021 - 6025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tuxhorn, G. E. Ayala, M. J. Smith, V. C. Smith, T. D. Dang, and D. R. Rowley Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling Clin. Cancer Res., September 1, 2002; 8(9): 2912 - 2923. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
